Clinical Trial Update: GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype [Phase 2]

View source ↗

Summary

Phase 2 study of GS-5885 (ledipasvir) and GS-9451 in combination with peginterferon alfa-2a and ribavirin for treatment-naïve chronic genotype 1 hepatitis C pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GS-5885 (Ledipasvir) (Ledipasvir)
• GS-9451 (GS-9451)
• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis C | Phase 2 | Status: TERMINATED